Saturday, 31 October 2026European Markets

ENSURGE MICROPOWER Stock 12.75% Up On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with ENSURGE MICROPOWER (ENSU.OL) rising 12.75% to kr1.38 on Thursday while Oslo Børs Benchmark Index_GI fell 0.08% to kr1,424.87.

ENSURGE MICROPOWER's last close was kr1.23, 70.73% under its 52-week high of kr4.19.

About ENSURGE MICROPOWER

Ensurge Micropower ASA provides energy storage solutions for wearable devices, connected sensors, and other applications in Norway. The company offers solid-state lithium battery technology that enables it to produce rechargeable batteries. It serves hearables, medical and sports/fitness wearables, and home and industrial devices sectors. The company was formerly known as Thin Film Electronics ASA and changed its name to Ensurge Micropower ASA in June 2021. Ensurge Micropower ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ENSURGE MICROPOWER has a trailing twelve months EPS of kr-3.32.

Volume

Today's last reported volume for ENSURGE MICROPOWER is 4895430 which is 22.9% above its average volume of 3983000.

Moving Average

ENSURGE MICROPOWER's worth is way above its 50-day moving average of kr0.12 and way above its 200-day moving average of kr0.76.

More news about ENSURGE MICROPOWER (ENSU.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com